Do analysts recommend BLGO or AMTX?

Aemetis has a consensus target price of $8.92, suggesting a potential upside of 354.93%. Given Aemetis' stronger consensus rating and higher probable upside, analysts clearly believe Aemetis is more favorable than BioLargo. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioLargo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Aemetis 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Is BLGO or AMTX more profitable?

BioLargo has a net margin of -11.45% compared to Aemetis' net margin of -35.43%. Aemetis' return on equity of 0.00% beat BioLargo's return on equity. Company Net Margins Return on Equity Return on Assets BioLargo -11.45% -39.90% -22.06% Aemetis -35.43% N/A -33.44%

Do analysts recommend SAFX or BLGO?

XCF Global Capital currently has a consensus target price of $0.40, indicating a potential upside of 17.65%. Given XCF Global Capital's stronger consensus rating and higher possible upside, research analysts plainly believe XCF Global Capital is more favorable than BioLargo. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XCF Global Capital 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 BioLargo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts rate ARQ or BLGO?

ARQ presently has a consensus target price of $7.50, suggesting a potential upside of 179.85%. Given ARQ's stronger consensus rating and higher possible upside, equities analysts clearly believe ARQ is more favorable than BioLargo. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ARQ 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60 BioLargo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger valuation and earnings, ARQ or BLGO?

BioLargo has lower revenue, but higher earnings than ARQ. BioLargo is trading at a lower price-to-earnings ratio than ARQ, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ARQ $120.34M 0.96 -$52.61M -$1.29 N/A BioLargo $12.23M 3.15 -$3.50M -$0.04 N/A

Is ARQ or BLGO more profitable?

BioLargo has a net margin of -11.45% compared to ARQ's net margin of -43.93%. ARQ's return on equity of -2.67% beat BioLargo's return on equity. Company Net Margins Return on Equity Return on Assets ARQ -43.93% -2.67% -2.00% BioLargo -11.45% -39.90% -22.06%

Do analysts rate CBUS or BLGO?

Cibus presently has a consensus price target of $9.00, indicating a potential upside of 631.71%. Given Cibus' stronger consensus rating and higher probable upside, analysts plainly believe Cibus is more favorable than BioLargo. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cibus 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 BioLargo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable valuation and earnings, CBUS or BLGO?

BioLargo has higher revenue and earnings than Cibus. BioLargo is trading at a lower price-to-earnings ratio than Cibus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cibus $3.64M 25.79 -$127.08M -$1.97 N/A BioLargo $12.23M 3.15 -$3.50M -$0.04 N/A

Is CBUS or BLGO more profitable?

BioLargo has a net margin of -11.45% compared to Cibus' net margin of -2,366.33%. BioLargo's return on equity of -39.90% beat Cibus' return on equity. Company Net Margins Return on Equity Return on Assets Cibus -2,366.33% -200.87% -28.28% BioLargo -11.45% -39.90% -22.06%

Do analysts recommend BLGO or FSI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioLargo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Flexible Solutions International 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

BioLargo (BLGO) Competitors

$0.12 0.00 (0.00%)

As of 06/12/2026 03:57 PM Eastern

Compare

BLGO vs. AMTX, SAFX, ARQ, CBUS, and FSI

Should you buy BioLargo stock or one of its competitors? MarketBeat compares BioLargo with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BioLargo include Aemetis (AMTX), XCF Global Capital (SAFX), ARQ (ARQ), Cibus (CBUS), and Flexible Solutions International (FSI). These companies are all part of the "chemicals" industry.

How does BioLargo compare to Aemetis?

BioLargo (NASDAQ:BLGO) and Aemetis (NASDAQ:AMTX) are both small-cap chemicals companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, media sentiment and institutional ownership.

In the previous week, Aemetis had 3 more articles in the media than BioLargo. MarketBeat recorded 3 mentions for Aemetis and 0 mentions for BioLargo. Aemetis' average media sentiment score of 0.91 beat BioLargo's score of 0.00 indicating that Aemetis is being referred to more favorably in the news media.

Company	Overall Sentiment
BioLargo	Neutral
Aemetis	Positive

BioLargo has higher earnings, but lower revenue than Aemetis. BioLargo is trading at a lower price-to-earnings ratio than Aemetis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLargo	$12.23M	3.15	-$3.50M	-$0.04	N/A
Aemetis	$197.63M	0.70	-$77M	-$1.19	N/A

BioLargo has a beta of -0.14, meaning that its share price is 114% less volatile than the broader market. Comparatively, Aemetis has a beta of 1.37, meaning that its share price is 37% more volatile than the broader market.

BioLargo has a net margin of -11.45% compared to Aemetis' net margin of -35.43%. Aemetis' return on equity of 0.00% beat BioLargo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioLargo	-11.45%	-39.90%	-22.06%
Aemetis	-35.43%	N/A	-33.44%

Aemetis has a consensus target price of $8.92, suggesting a potential upside of 354.93%. Given Aemetis' stronger consensus rating and higher probable upside, analysts clearly believe Aemetis is more favorable than BioLargo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLargo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Aemetis	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

0.0% of BioLargo shares are held by institutional investors. Comparatively, 27.0% of Aemetis shares are held by institutional investors. 19.3% of BioLargo shares are held by insiders. Comparatively, 13.0% of Aemetis shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Aemetis beats BioLargo on 10 of the 16 factors compared between the two stocks.

How does BioLargo compare to XCF Global Capital?

XCF Global Capital (NASDAQ:SAFX) and BioLargo (NASDAQ:BLGO) are both small-cap chemicals companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment and institutional ownership.

XCF Global Capital has a beta of -0.34, meaning that its stock price is 134% less volatile than the broader market. Comparatively, BioLargo has a beta of -0.14, meaning that its stock price is 114% less volatile than the broader market.

In the previous week, XCF Global Capital had 4 more articles in the media than BioLargo. MarketBeat recorded 4 mentions for XCF Global Capital and 0 mentions for BioLargo. XCF Global Capital's average media sentiment score of 0.65 beat BioLargo's score of 0.00 indicating that XCF Global Capital is being referred to more favorably in the media.

Company	Overall Sentiment
XCF Global Capital	Positive
BioLargo	Neutral

XCF Global Capital has a net margin of 300.85% compared to BioLargo's net margin of -11.45%. BioLargo's return on equity of -39.90% beat XCF Global Capital's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XCF Global Capital	300.85%	-588.22%	-29.08%
BioLargo	-11.45%	-39.90%	-22.06%

52.3% of XCF Global Capital shares are held by institutional investors. Comparatively, 0.0% of BioLargo shares are held by institutional investors. 0.1% of XCF Global Capital shares are held by insiders. Comparatively, 19.3% of BioLargo shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

XCF Global Capital has higher revenue and earnings than BioLargo. BioLargo is trading at a lower price-to-earnings ratio than XCF Global Capital, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XCF Global Capital	$20.82M	5.43	$74.02M	-$0.68	N/A
BioLargo	$12.23M	3.15	-$3.50M	-$0.04	N/A

XCF Global Capital currently has a consensus target price of $0.40, indicating a potential upside of 17.65%. Given XCF Global Capital's stronger consensus rating and higher possible upside, research analysts plainly believe XCF Global Capital is more favorable than BioLargo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XCF Global Capital	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
BioLargo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

XCF Global Capital beats BioLargo on 10 of the 15 factors compared between the two stocks.

How does BioLargo compare to ARQ?

ARQ (NASDAQ:ARQ) and BioLargo (NASDAQ:BLGO) are both small-cap chemicals companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment, risk and earnings.

ARQ presently has a consensus target price of $7.50, suggesting a potential upside of 179.85%. Given ARQ's stronger consensus rating and higher possible upside, equities analysts clearly believe ARQ is more favorable than BioLargo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ARQ	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
BioLargo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

BioLargo has lower revenue, but higher earnings than ARQ. BioLargo is trading at a lower price-to-earnings ratio than ARQ, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ARQ	$120.34M	0.96	-$52.61M	-$1.29	N/A
BioLargo	$12.23M	3.15	-$3.50M	-$0.04	N/A

BioLargo has a net margin of -11.45% compared to ARQ's net margin of -43.93%. ARQ's return on equity of -2.67% beat BioLargo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ARQ	-43.93%	-2.67%	-2.00%
BioLargo	-11.45%	-39.90%	-22.06%

ARQ has a beta of 1.99, meaning that its stock price is 99% more volatile than the broader market. Comparatively, BioLargo has a beta of -0.14, meaning that its stock price is 114% less volatile than the broader market.

In the previous week, ARQ had 1 more articles in the media than BioLargo. MarketBeat recorded 1 mentions for ARQ and 0 mentions for BioLargo. ARQ's average media sentiment score of 0.93 beat BioLargo's score of 0.00 indicating that ARQ is being referred to more favorably in the media.

Company	Overall Sentiment
ARQ	Positive
BioLargo	Neutral

18.5% of ARQ shares are held by institutional investors. Comparatively, 0.0% of BioLargo shares are held by institutional investors. 20.1% of ARQ shares are held by company insiders. Comparatively, 19.3% of BioLargo shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

ARQ beats BioLargo on 13 of the 17 factors compared between the two stocks.

How does BioLargo compare to Cibus?

Cibus (NASDAQ:CBUS) and BioLargo (NASDAQ:BLGO) are both small-cap chemicals companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings.

Cibus presently has a consensus price target of $9.00, indicating a potential upside of 631.71%. Given Cibus' stronger consensus rating and higher probable upside, analysts plainly believe Cibus is more favorable than BioLargo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cibus	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
BioLargo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Cibus has a beta of 1.64, suggesting that its stock price is 64% more volatile than the broader market. Comparatively, BioLargo has a beta of -0.14, suggesting that its stock price is 114% less volatile than the broader market.

In the previous week, Cibus had 4 more articles in the media than BioLargo. MarketBeat recorded 4 mentions for Cibus and 0 mentions for BioLargo. Cibus' average media sentiment score of 0.80 beat BioLargo's score of 0.00 indicating that Cibus is being referred to more favorably in the media.

Company	Overall Sentiment
Cibus	Positive
BioLargo	Neutral

BioLargo has higher revenue and earnings than Cibus. BioLargo is trading at a lower price-to-earnings ratio than Cibus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cibus	$3.64M	25.79	-$127.08M	-$1.97	N/A
BioLargo	$12.23M	3.15	-$3.50M	-$0.04	N/A

33.8% of Cibus shares are owned by institutional investors. Comparatively, 0.0% of BioLargo shares are owned by institutional investors. 49.4% of Cibus shares are owned by company insiders. Comparatively, 19.3% of BioLargo shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

BioLargo has a net margin of -11.45% compared to Cibus' net margin of -2,366.33%. BioLargo's return on equity of -39.90% beat Cibus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cibus	-2,366.33%	-200.87%	-28.28%
BioLargo	-11.45%	-39.90%	-22.06%

Summary

Cibus beats BioLargo on 10 of the 16 factors compared between the two stocks.

How does BioLargo compare to Flexible Solutions International?

BioLargo (NASDAQ:BLGO) and Flexible Solutions International (NYSE:FSI) are both small-cap chemicals companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, profitability, risk, institutional ownership, dividends, media sentiment, valuation and earnings.

BioLargo has a beta of -0.14, meaning that its stock price is 114% less volatile than the broader market. Comparatively, Flexible Solutions International has a beta of 1.65, meaning that its stock price is 65% more volatile than the broader market.

Flexible Solutions International has a net margin of 10.80% compared to BioLargo's net margin of -11.45%. Flexible Solutions International's return on equity of 10.61% beat BioLargo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioLargo	-11.45%	-39.90%	-22.06%
Flexible Solutions International	10.80%	10.61%	7.32%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLargo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Flexible Solutions International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Flexible Solutions International has higher revenue and earnings than BioLargo. BioLargo is trading at a lower price-to-earnings ratio than Flexible Solutions International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLargo	$12.23M	3.15	-$3.50M	-$0.04	N/A
Flexible Solutions International	$39.34M	2.04	$2.78M	$0.06	105.17

0.0% of BioLargo shares are held by institutional investors. Comparatively, 54.3% of Flexible Solutions International shares are held by institutional investors. 19.3% of BioLargo shares are held by company insiders. Comparatively, 35.8% of Flexible Solutions International shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Flexible Solutions International had 1 more articles in the media than BioLargo. MarketBeat recorded 1 mentions for Flexible Solutions International and 0 mentions for BioLargo. Flexible Solutions International's average media sentiment score of 0.44 beat BioLargo's score of 0.00 indicating that Flexible Solutions International is being referred to more favorably in the news media.

Company	Overall Sentiment
BioLargo	Neutral
Flexible Solutions International	Neutral

Summary

Flexible Solutions International beats BioLargo on 14 of the 15 factors compared between the two stocks.

Get BioLargo News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BLGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BLGO vs. The Competition

Export

Metric	BioLargo	Chemicals & allied products Industry	Construction Sector	NASDAQ Exchange
Market Cap	$38.51M	$7.93B	$9.80B	$12.05B
Dividend Yield	N/A	1.09%	1.90%	5.66%
P/E Ratio	-12.00	N/A	18.48	24.42
Price / Sales	3.15	2.66	4.18	118.72
Price / Cash	N/A	270.17	17.30	37.92
Price / Book	12.00	7.44	5.26	6.82
Net Income	-$3.50M	$659.84M	$563.99M	$337.56M
7 Day Performance	-19.73%	-6.58%	1.51%	1.16%
1 Month Performance	-9.50%	-3.27%	17.68%	3.16%
1 Year Performance	-40.00%	-12.51%	14.18%	30.60%

BioLargo Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BLGO BioLargo	N/A	$0.12 flat	N/A	-40.0%	$38.51M	$12.23M	N/A	30
AMTX Aemetis	2.817 of 5 stars	$2.03 +0.7%	$8.92 +340.3%	+1.6%	$141.79M	$219.71M	N/A	160
SAFX XCF Global Capital	2.7789 of 5 stars	$0.38 +1.1%	$0.40 +4.4%	N/A	$127.37M	$20.82M	N/A	N/A	Gap Up
ARQ ARQ	4.4094 of 5 stars	$2.68 +0.2%	$7.50 +180.4%	-46.2%	$114.74M	$122.14M	N/A	140	Positive News
CBUS Cibus	1.6992 of 5 stars	$1.21 +0.8%	$9.00 +644.4%	-17.2%	$92.29M	$4.29M	N/A	48	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BLGO) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioLargo (BLGO) Competitors